Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. has announced a pilot program at King’s College Hospital to test its Steriwave technology, a revolutionary light-activated antimicrobial treatment designed to prevent hospital-acquired infections. This innovative approach, already adopted by some NHS hospitals, offers a promising alternative to antibiotics by rapidly eliminating pathogens without giving them a chance to develop resistance.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
